July 26th 2024
Primary and secondary pharmacokinetic parameters through day 75 were similar across treatment arms.
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Maximilian Vargas, PhD, MBA: The Impact of the Inflation Reduction Act on Biosimilar Uptake
The Inflation Reduction Act contains a provision that boosts reimbursement to physicians to encourage the adoption of biosimilars and allows biosimilars to have lower list prices, benefiting patients' out-of-pocket costs.
Ross Maltz, MD: Understanding Biosimilar Acceptance in Pediatric Gastroenterologists
As previous studies have shown slow uptake of biosimilars, Ross Maltz, MD, and his team wanted to get a better understanding of this issue using a survey focused on pediatric gastroenterologists.
Infliximab Monotherapy, Combination Therapy Comparable Among Biologic-Naïve Patients With IBD
At week 54, there were no significant differences in patients achieving the target exposure (5 µg/mL) between those in the monotherapy cohort and those in the combination therapy cohort.
Most Pediatric Gastroenterologists Comfortable With Prescribing Infliximab Biosimilar
Among pediatric gastroenterologists surveyed, most were comfortable prescribing an infliximab biosimilar to patients who were tumor necrosis factor (TNF)-naïve and switching to a biosimilar for those in clinical remission.
Study Details Perceptions of Biosimilars Among Patients with Immune-Mediated Diseases
April 11th 2023An analysis of survey data from 500 patients with immune-mediated diseases, including rheumatoid arthritis, psoriasis, and IBD, suggests fewer than 1-in-4 patients were knowledgeable on the concept of biosimilars, but were open to learning more and considering use.
Juliana Reed, MS: The Future of Biosimilars in the US Market
Juliana Reed, MS, believes that there should be legislative incentives and preferred status for lower cost biosimilars in all government programs, with robust competition and accountability for PBMs not to limit access.
Rheumatology Month in Review: March 2023
The March 2023 rheumatology month in review highlights recent data regarding nipocalimab as a treatment option for hemolytic disease of the fetus and newborn and myasthenia gravis, hyperbaric oxygen therapy for fibromyalgia, and the differences among specialties in biosimilar uptake.
Juliana Reed, MS: The Implications of Pharmacy Benefit Managers Prioritizing Profit Over Patients
The Biosimilars Forum is concerned with the limited access to lower-cost biosimilars, specifically regarding the 8 adalimumab biosimilars set to launch in July, due to pharmacy benefits managers controlling access to 80% of the US market.
Adalimumab Biosimilar for Uveitis Similarly Efficacious to Bio-Originator
March 22nd 2023Data from the United Kingdom indicate Amgevita is safe and effective for non-infectious uveitis with non-inferiority to originator adalimumab, but a significant number of patients requested to switch back due to adverse events.
FDA Approves High-Concentration Formulation Biosimilar Adalimumab-Adaz
The approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of adalimumab 50 mg/mL and adalimumab high-concentration formulation.